Neurocrine Biosciences, Inc. (NBIX)
Automate Your Wheel Strategy on NBIX
With Tiblio's Option Bot, you can configure your own wheel strategy including NBIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NBIX
- Rev/Share 26.9889
- Book/Share 30.2173
- PB 4.4935
- Debt/Equity 0.1426
- CurrentRatio 3.3831
- ROIC 0.1033
- MktCap 13500229043.0
- FreeCF/Share 5.9668
- PFCF 22.7621
- PE 31.5345
- Debt/Assets 0.1004
- DivYield 0
- ROE 0.1582
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NBIX | Morgan Stanley | Overweight | Equal Weight | -- | $175 | Jan. 8, 2026 |
| Initiation | NBIX | Citigroup | -- | Buy | -- | $175 | Oct. 21, 2025 |
| Initiation | NBIX | Truist | -- | Buy | -- | $163 | July 21, 2025 |
| Initiation | NBIX | Goldman | -- | Buy | -- | $182 | July 10, 2025 |
| Upgrade | NBIX | Needham | Hold | Buy | -- | $138 | April 15, 2025 |
| Upgrade | NBIX | RBC Capital Mkts | Sector Perform | Outperform | -- | $137 | April 14, 2025 |
| Initiation | NBIX | Deutsche Bank | -- | Hold | -- | $138 | Feb. 11, 2025 |
| Resumed | NBIX | Raymond James | -- | Outperform | -- | $155 | Oct. 10, 2024 |
| Upgrade | NBIX | Piper Sandler | Neutral | Overweight | $131 | $159 | Aug. 29, 2024 |
News
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Published: April 04, 2025 by: PRNewsWire
Sentiment: Neutral
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
Read More
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference SAN DIEGO , March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily INGREZZA® (valbenazine) capsules. This analysis was presented at the 2025 Psychiatry Update Conference in Chicago.
Read More
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you work in the biotech industry, you might know the name Alex Denner.
Read More
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
Read More
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Read More
About Neurocrine Biosciences, Inc. (NBIX)
- IPO Date 1996-05-23
- Website https://www.neurocrine.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kyle W. Gano
- Employees 1800